Furthermore, NKCC1 promoted the EMT‐like process in gliomas via the RhoA and Rac1 signaling pathways; inhibition of NKCC1 significantly impaired the aggressive progression of gliomas in vitro and in vivo, which indicated that NKCC1 serves as a potential therapeutic target for the inhibition of the dissemination of gliomas. Here, RHOA is linked to glioma.